Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

Background: The benefit of chemotherapy combined with immunotherapy in EGFR-mutant lung adenocarcinoma (LUAD) patients whose tumor developed resistance to EGFR tyrosine kinase inhibitors (TKIs) is not thoroughly investigated. The goal of this retrospective cohort study is to assess the clinical effi...

Full description

Bibliographic Details
Main Authors: Lingzhi Hong, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, Simon Heeke, Amy R. Spelman, Yasir Y. Elamin, Marcelo V. Negrao, Boris Sepesi, Don L. Gibbons, J. Jack Lee, Jia Wu, Natalie I. Vokes, John V. Heymach, Jianjun Zhang, Xiuning Le
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
lung adenocarcinoma
EGFR
tyrosine kinase inhibitors
immunotherapy
chemotherapy
Online Access:https://www.mdpi.com/2072-6694/14/14/3473

Internet

https://www.mdpi.com/2072-6694/14/14/3473

Similar Items